This story originally appeared in the May 2026 edition of our sister publication, South Sound Business.
A Tacoma pharmaceutical company whose backers include several well-known Northwest families hopes to offer a drug in the next four years that, studies show, can save brain tissue in people who have suffered an ischemic stroke and receive the drug intravenously for 48 hours immediately after surgeons remove the stroke-causing clot from the patient’s brain.
“We know that our drug is getting to the brain and it’s saving brain, now we just have to measure what the Food and Drug Administration requires regarding a new stroke treatment, which is your function: Can you walk? Are you in a wheelchair? How disabled are you post-stroke? Or can you go back to your normal life post-stroke? That’s the goal,” said Greg Archambeau, president of Revalesio…